Agency Forms Undergoing Paperwork Reduction Act Review, 30462-30463 [2015-12808]
Download as PDF
<![CDATA[
30462
Federal Register / Vol. 80, No. 102 / Thursday, May 28, 2015 / Notices
‘‘Notice–2015–QVO–01, Federal
Procurement Data System Product and
Service Codes Manual Update,’’ on your
attached document.
• Mail: General Services
Administration, Regulatory Secretariat
Division (MVCB), 1800 F Street NW.,
Washington, DC 20405. ATTN: Ms.
Flowers.
Instructions: Please submit comments
only and cite Notice–2015–QVO–01,
Federal Procurement Data System
Product and Service Codes Manual
Update, in all correspondence related to
this notice. All comments received will
be posted without change to https://
www.regulations.gov, including any
personal and/or business confidential
information provided.
FOR FURTHER INFORMATION CONTACT: Ms.
Pat Brooks at pat.brooks@gsa.gov or
703–605–3406.
SUPPLEMENTARY INFORMATION: The
Product and Service Codes (PSC)
Manual provides codes to describe
products, services, and research and
development purchased by the
government. The codes are one of the
data elements reported in the Federal
Procurement Data System (FPDS). The
GSA, which maintains the PSC Manual,
is in the process of updating the
manual. The update includes the
addition, deletion or revisions of codes.
The list of PSC code revisions is titled
‘‘Notice–2015–QVO–01; Docket No.
2015–0002; Sequence 12, Federal
Procurement Data System Product and
Service Codes Manual’’ and is viewable
and searchable on regulation.gov. The
current manual titled ‘‘Federal
Procurement Data System Product and
Service Codes Manual, August 2011
Edition’’ is also posted on
regulation.gov. A thirty (30) day
comment period is available.
Dated: May 19, 2015.
Karen Kopf,
Acting Assistant Commissioner, Integrated
Award Environment, Federal Acquisition
Service.
Proposed Project
Using Rapid Assessment Methods to
Understand Issues in HIV Prevention,
Care and Treatment in the United
States—New—National Center for HIV/
AIDS, Viral Hepatitis, STD, and TB
Prevention (NCHHSTP), Centers for
Disease Control and Prevention (CDC).
[FR Doc. 2015–12891 Filed 5–27–15; 8:45 am]
BILLING CODE 6820–89–P
asabaliauskas on DSK5VPTVN1PROD with NOTICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–15–14APJ]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
VerDate Sep<11>2014
18:18 May 27, 2015
Jkt 235001
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Background and Brief Description
The Centers for Disease Control and
Prevention requests approval for a 3year clearance to collect data using
rapid qualitative inquiries to understand
issues related to HIV prevention, care,
and treatment in the United States.
Rapid inquiries are concentrated data
collection and iterative data analytic
efforts focused on timely and relevant
responses to urgent issues and research
questions. Although we will collect the
PO 00000
Frm 00032
Fmt 4703
Sfmt 4703
majority of data using qualitative
methods, many studies covered under
this generic information collection, will
involve a mixed methods approach for
data collection.
The rapid inquiries will include
multiple well-established qualitative
methodologies, which may include but
not be limited to in-depth individual
interviews, focus groups, direct
observations, case studies, document
reviews, or brief quantitative surveys
assessing demographics, behaviors,
attitudes, intentions, beliefs, or other
attributes of the respondents. In some
assessments, additional contextual
information may be collected, such as
information about the respondents’
community, workplaces, or
organizations and places where they
interact. CDC expects to collect
qualitative data from approximately
1,800 respondents, assuming three
research studies per year with each
research study collecting data from 200
respondents.
For all proposed studies under this
generic information collection, our
efforts are expected to provide insight
regarding a wide array of HIV-related
programs designed for various
populations throughout the United
States, including but not limited to:
Persons living with HIV/AIDS (PLWH);
persons at elevated risk for acquiring
new HIV infection or transmitting
existing HIV infection to others;
clinicians or other HIV care providers;
men who have sex with men (MSM);
transgender persons; injection and
noninjection drug users; incarcerated
populations or ex-prisoners; commercial
sex workers; male and female
heterosexual groups at high risk for HIV
infection; and other providers and
organizations (e.g., health departments,
community-based organizations, public
and private health clinics, advocacy
groups, community groups, or other
governmental and nongovernmental
organizations) serving or otherwise
interacting with persons at greatest need
for HIV prevention, care, and treatment.
Recruitment procedures will vary
slightly based on the target population
and research design of each information
collection submitted under this generic
information collection. Partner
organizations such as public and private
health clinics and community-based
organizations that serve the target
populations in the respective geographic
locations may be contacted for their
assistance in recruitment of potential
respondents. Respondents may be
identified and selected as key
informants and invited to participate by
contractor staff members.
E:\FR\FM\28MYN1.SGM
28MYN1
30463
Federal Register / Vol. 80, No. 102 / Thursday, May 28, 2015 / Notices
Sampling recruitment methods may
include, but not be limited to: Use of
social networking sites, the Internet,
print marketing materials, and other
methods to find and enroll respondents
into the research study.
All data collection tools will be
pretested and interviews conducted by
trained personnel. The data collection
will take place at a time and place that
is convenient to the respondent.
Locations will be private. Data
collection may be audio-recorded and
transcribed with the consent of the
respondent.
The data collections supported under
this generic information collection will
be used to provide insight regarding
barriers and facilitators to HIV
prevention, care, and treatment in the
United States and territories, and thus
suggest ways CDC might improve
programmatic activities along the
continuum of HIV prevention, treatment
and care.
The total estimated annualized
burden hours are 918. There are no costs
to respondents other than their time.
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent
General
General
General
General
General
General
General
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Public—Adults
Number of
respondents
Form name
...................................
...................................
...................................
...................................
...................................
...................................
...................................
Study Screener ..............................................
Contact Information Form ..............................
Consent Form ................................................
Demographic Survey ......................................
Interview Guide ..............................................
Provider Demographic Survey .......................
Provider Interview Guide ................................
Leroy A. Richardson,
Chief, Information Collection Review Office,
Office of Scientific Integrity, Office of the
Associate Director for Science, Office of the
Director, Centers for Disease Control and
Prevention.
instructions for submitting comments
can be found at www.regulations.gov.
This guidance document does not
have the force and effect of law.
[FR Doc. 2015–12808 Filed 5–27–15; 8:45 am]
• DATES:
• ADDRESSES:
• FOR FURTHER INFORMATION
CONTACT:
• SUPPLEMENTARY INFORMATION:
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[CDC–2015–0034; NIOSH 233–A]
NIOSH List of Antineoplastic and Other
Hazardous Drugs in Healthcare
Settings: Proposed Additions to the
NIOSH Hazardous Drug List 2016;
Request for Comment
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of draft document
available for public comment.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the availability of the
following draft document for public
comment entitled ‘‘NIOSH List of
Antineoplastic and Other Hazardous
Drugs in Healthcare Settings: Proposed
Additions to the NIOSH Hazardous
Drug List 2016.’’ The document and
asabaliauskas on DSK5VPTVN1PROD with NOTICES
VerDate Sep<11>2014
18:18 May 27, 2015
Jkt 235001
Electronic or written comments
must be received by July 27, 2015.
ADDRESSES: You may submit comments,
identified by CDC–2015–0034 and
Docket Number NIOSH 233–A, by either
of the two following methods:
• Federal eRulemaking Portal:
www.regulations.gov Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226.
Instructions: All information received
in response to this notice must include
the agency name and the docket number
(CDC–2015–0034; NIOSH 233–A). All
relevant comments received will be
posted without change to
www.regulations.gov, including any
personal information provided. All
electronic comments should be
formatted as Microsoft Word. Please
make reference to CDC–2015–0034 and
Docket Number NIOSH 233–A. All
information received in response to this
notice will also be available for public
examination and copying at the NIOSH
Docket Office, 1150 Tusculum Avenue,
Room 155, Cincinnati, OH 45226.
FOR FURTHER INFORMATION CONTACT:
Barbara MacKenzie, NIOSH, Division of
DATES:
Centers for Disease Control and
Prevention
SUMMARY:
Table of Contents
PO 00000
Frm 00033
Fmt 4703
Sfmt 4703
Number of
responses per
respondent
1,600
600
600
500
500
100
100
1
1
1
1
1
1
1
Average
burden per
response
(in hours)
5/60
1/60
5/60
15/60
1
15/60
45/60
Applied Research and Technology,
Robert A. Taft Laboratories, 1090
Tusculum Avenue, MS C–26,
Cincinnati, Ohio 45226. (513) 533–8132
(not a toll free number). Email:
hazardousdrugs@cdc.gov.
SUPPLEMENTARY INFORMATION: The
NIOSH Alert: ‘‘Preventing Occupational
Exposures to Antineoplastic and Other
Hazardous Drugs in Health Care
Settings’’ was published in September
2004 (https://www.cdc.gov/niosh/docs/
2004-165/). This Alert contained
Appendix A which was a list of drugs
that were deemed to be hazardous and
may require special handling. This list
of hazardous drugs was updated in
2010, 2012 and 2014 and covered all
new approved drugs and drugs with
new warnings up to December 2011
(https://www.cdc.gov/niosh/docs/2014138). Between January 2012 and
December 2013, 60 new drugs received
FDA approval and 270 drugs received
new warnings based on reported
adverse effects in patients. From this list
of 330 drugs, 44 drugs were identified
by NIOSH as potential hazardous drugs.
In addition to these 44 drugs, the panel
members were asked to comment on the
addition of one drug requested by
several stakeholders. Three additional
drugs had safe handling
recommendations from the
manufacturer and NIOSH is following
these recommendations. Therefore,
these 3 drugs will be listed as hazardous
without requiring further review. A
panel consisting of peer reviewers and
stakeholders was asked to review and
comment on the 45 potentially
hazardous drugs. Reviewers were not
asked to provide a consensus opinion
E:\FR\FM\28MYN1.SGM
28MYN1
]]>Agencies
[Federal Register Volume 80, Number 102 (Thursday, May 28, 2015)]
[Notices]
[Pages 30462-30463]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-12808]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30Day-15-14APJ]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice should be
directed to the Attention: CDC Desk Officer, Office of Management and
Budget, Washington, DC 20503 or by fax to (202) 395-5806. Written
comments should be received within 30 days of this notice.
Proposed Project
Using Rapid Assessment Methods to Understand Issues in HIV
Prevention, Care and Treatment in the United States--New--National
Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP),
Centers for Disease Control and Prevention (CDC).
Background and Brief Description
The Centers for Disease Control and Prevention requests approval
for a 3-year clearance to collect data using rapid qualitative
inquiries to understand issues related to HIV prevention, care, and
treatment in the United States. Rapid inquiries are concentrated data
collection and iterative data analytic efforts focused on timely and
relevant responses to urgent issues and research questions. Although we
will collect the majority of data using qualitative methods, many
studies covered under this generic information collection, will involve
a mixed methods approach for data collection.
The rapid inquiries will include multiple well-established
qualitative methodologies, which may include but not be limited to in-
depth individual interviews, focus groups, direct observations, case
studies, document reviews, or brief quantitative surveys assessing
demographics, behaviors, attitudes, intentions, beliefs, or other
attributes of the respondents. In some assessments, additional
contextual information may be collected, such as information about the
respondents' community, workplaces, or organizations and places where
they interact. CDC expects to collect qualitative data from
approximately 1,800 respondents, assuming three research studies per
year with each research study collecting data from 200 respondents.
For all proposed studies under this generic information collection,
our efforts are expected to provide insight regarding a wide array of
HIV-related programs designed for various populations throughout the
United States, including but not limited to: Persons living with HIV/
AIDS (PLWH); persons at elevated risk for acquiring new HIV infection
or transmitting existing HIV infection to others; clinicians or other
HIV care providers; men who have sex with men (MSM); transgender
persons; injection and noninjection drug users; incarcerated
populations or ex-prisoners; commercial sex workers; male and female
heterosexual groups at high risk for HIV infection; and other providers
and organizations (e.g., health departments, community-based
organizations, public and private health clinics, advocacy groups,
community groups, or other governmental and nongovernmental
organizations) serving or otherwise interacting with persons at
greatest need for HIV prevention, care, and treatment.
Recruitment procedures will vary slightly based on the target
population and research design of each information collection submitted
under this generic information collection. Partner organizations such
as public and private health clinics and community-based organizations
that serve the target populations in the respective geographic
locations may be contacted for their assistance in recruitment of
potential respondents. Respondents may be identified and selected as
key informants and invited to participate by contractor staff members.
[[Page 30463]]
Sampling recruitment methods may include, but not be limited to:
Use of social networking sites, the Internet, print marketing
materials, and other methods to find and enroll respondents into the
research study.
All data collection tools will be pretested and interviews
conducted by trained personnel. The data collection will take place at
a time and place that is convenient to the respondent. Locations will
be private. Data collection may be audio-recorded and transcribed with
the consent of the respondent.
The data collections supported under this generic information
collection will be used to provide insight regarding barriers and
facilitators to HIV prevention, care, and treatment in the United
States and territories, and thus suggest ways CDC might improve
programmatic activities along the continuum of HIV prevention,
treatment and care.
The total estimated annualized burden hours are 918. There are no
costs to respondents other than their time.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of burden per
Type of respondent Form name respondents responses per response (in
respondent hours)
----------------------------------------------------------------------------------------------------------------
General Public--Adults................ Study Screener.......... 1,600 1 5/60
General Public--Adults................ Contact Information Form 600 1 1/60
General Public--Adults................ Consent Form............ 600 1 5/60
General Public--Adults................ Demographic Survey...... 500 1 15/60
General Public--Adults................ Interview Guide......... 500 1 1
General Public--Adults................ Provider Demographic 100 1 15/60
Survey.
General Public--Adults................ Provider Interview Guide 100 1 45/60
----------------------------------------------------------------------------------------------------------------
Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific
Integrity, Office of the Associate Director for Science, Office of the
Director, Centers for Disease Control and Prevention.
[FR Doc. 2015-12808 Filed 5-27-15; 8:45 am]
BILLING CODE 4163-18-P
